Aurobindo receives tentative FDA OK for abacavir sulfate/lamivudine
This article was originally published in Scrip
Aurobindo Pharmahas received tentative approval from the US FDAto manufacture and market abacavir sulfate/lamivudine tablets 600mg/300mg, a generic version of GlaxoSmithKline's Epzicom tablets. The product was reviewed under the President's emergency plan for AIDS relief (PEPFAR), Aurobindo informed the Bombay Stock Exchange. The product represents Aurobindo's 76th ANDA approval by the FDA.
You may also be interested in...
Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.
Glenmark’s innovation spin-out initiates efforts to raise capital in the US, unfazed by mixed top-line results for its investigational atopic dermatitis treatment. Its parent firm has underscored the value proposition of the oncology franchise and proprietary bispecific antibody technology platform.
COVID-19 has generated a mind-boggling one billion-plus mentions on social media, unleashing unstructured big data rich in insights. Experts explain why pharma may well want to“listen in” more raptly to such conversations across therapy areas while shaping some aspects of business strategy.